Capecitabine vs S-1 for Elderly Patients with Advanced Gastric Cancer
Author Information
Author(s): Lee J-L, Kang Y-K, Kang H J, Lee K-H, Zang D Y, Ryoo B-Y, Kim J G, Park S R, Kang W K, Shin D B, Ryu M-H, Chang H M, Kim T-W, Baek J H, Min Y J
Primary Institution: Asan Medical Center, University of Ulsan College of Medicine
Hypothesis
This study investigates the efficacy and safety of capecitabine compared to S-1 in elderly patients with advanced gastric cancer.
Conclusion
Both capecitabine and S-1 are safe, well tolerated, and effective as first-line treatments for elderly patients with advanced gastric cancer.
Supporting Evidence
- The overall response rate was 27.2% for capecitabine and 28.9% for S-1.
- Median overall survival was 9.5 months for capecitabine and 8.1 months for S-1.
- Both treatments were well tolerated with minimal severe adverse events.
Takeaway
This study looked at two medicines to help older people with stomach cancer, and found that both worked well and were safe to use.
Methodology
Elderly patients with advanced gastric cancer were randomly assigned to receive either capecitabine or S-1, and their responses were evaluated based on predefined criteria.
Potential Biases
There may be bias due to the open-label design and the exclusion of certain patient populations.
Limitations
The study was limited by its small sample size and the lack of statistical comparison between treatment groups.
Participant Demographics
The median age of participants was 71 years, with a range from 65 to 82 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 14.1–40.4 for capecitabine; 95% CI, 15.6–42.1 for S-1
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website